Read + Share
Ikezawa Y, Mizugaki H, Morita R, Tateishi K, et al. Current status of first-line treatment with pembrolizumab for non-small cell lung
cancer with high PD-L1 expression. Cancer Sci 2022 Apr 4. doi: 10.1111/cas.15361.
PMID: 35377496
|
 |
|
Ikezawa Y, Mizugaki H, Morita R, Tateishi K, et al. Current status of first-line treatment with pembrolizumab for non-small cell lung
cancer with high PD-L1 expression. Cancer Sci 2022 Apr 4. doi: 10.1111/cas.15361.
PMID: 35377496
|
|
|
|